Your Daily Healthcare Policy Briefing

Trump Administration Expands Drug Price Deals Amidst New Legal Challenge Over Family Planning Funds

• The Trump Administration announced nine new agreements with pharmaceutical manufacturers on August 31, 2026, to lower prescription drug prices for Americans by implementing "most-favored-nation" (MFN) pricing, which aligns U.S. prices with the lowest paid by other developed nations. These latest deals bring the total number of manufacturers with MFN agreements to 26, now covering an impressive 89% of the branded drug market, and are expected to provide State Medicaid programs access to MFN drug prices, potentially saving billions.

  Whitehouse GovPharmexec

• UPDATE: A coalition of 23 states, led by Attorney General Kathy Jennings, filed a lawsuit on August 31, 2026, challenging new federal policy that threatens to strip Title X family planning funding from states and providers. The lawsuit argues that the new conditions conflict with Title X's governing statute and were unlawfully imposed without the required notice-and-comment process, aiming to block enforcement and preserve access to critical reproductive healthcare services.

  Delaware Gov

• The Trump Administration also committed $149.3 million on August 31, 2026, through the federal Rural Health Transformation Program (RHTP) to enhance healthcare delivery in rural Arkansas. This investment is earmarked for upgrading rural healthcare infrastructure, expanding telehealth and patient-monitoring capabilities, and improving training for rural health providers, aiming to modernize care and expand access in underserved communities.

  Cms Gov